Akèy › Kansè tete negatif triple
Etid klinik pou Kansè tete negatif triple ap rekrite nan Etazini
147 etid pou Kansè tete negatif triple ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Atlanta, GA20 etid
- Arlington, VA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
- Tampa, FL15 etid
- New Haven, CT15 etid
- Grand Rapids, MI15 etid
- Queens, NY15 etid
- Seattle, WA14 etid
- Austin, TX13 etid
- Philadelphia, PA13 etid
- West Valley City, UT13 etid
- San Diego, CA13 etid
- Durham, NC12 etid
- Orlando, FL12 etid
- Denver, CO12 etid
- Baltimore, MD12 etid
- Rochester, MN11 etid
- Washington, DC11 etid
- Pittsburgh, PA11 etid
- Edison, NJ11 etid
- Miami, FL11 etid
- San Francisco, CA11 etid
- Baldwin Park, CA10 etid
- Cleveland, OH10 etid
- Salt Lake City, UT9 etid
- Oklahoma City, OK9 etid
- Jacksonville, FL9 etid
- Detroit, MI9 etid
- Indianapolis, IN9 etid
- Aurora, CO9 etid
- Portland, OR9 etid
Pa eta
- Alabama11 etid
- Arizona18 etid
- Arkansas3 etid
- Colorado21 etid
- Connecticut19 etid
- Delaware3 etid
- Distrik Columbia7 etid
- Florid47 etid
- Georgia26 etid
- Illinois20 etid
- Indiana13 etid
- Iowa8 etid
- Kalifòni53 etid
- Kansas5 etid
- Kentucky6 etid
- Lwizyàn6 etid
- Main3 etid
- Maryland18 etid
- Massachusetts26 etid
- Michigan28 etid
- Minnesota17 etid
- Missouri24 etid
- Nebraska6 etid
- Nevada6 etid
- New Jersey20 etid
- New Mexico3 etid
- New York46 etid
- North Carolina21 etid
- Ohio29 etid
- Oklahoma10 etid
- Oregon12 etid
- Pennsylvania23 etid
- Rhode Island4 etid
- South Carolina9 etid
- South Dakota7 etid
- Tennessee31 etid
- Texas59 etid
- Utah23 etid
- Virginia28 etid
- Washington20 etid
- Wisconsin7 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT07619534A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
Laj 19 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06586957177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07189871PRE-ISPY Phase I/II Oncology Platform Program
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05868226Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05422794First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06799065Study of AVZO-021 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05867251Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Ap rekrite
Laj 30 ak plis · Fanm · Mizajou Sep 25, 2026 · NCT02945579A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06841354Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Sep 25, 2026 · NCT07066189Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05528133A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07229313Intratumoral N17350 in Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07339176A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06618287Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07340541A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07705334A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07020117Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06353997Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.